Clinical trial
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Recruiting now · Phase 3 · 4 countries · Registry ID NCT07153471
Recruiting nowPhase 3Interventional
What this study is about
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionOsteoarthritis
Full registry criteria
Inclusion Criteria: * Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening * Have tried at least once to lose weight through diet but were unsuccessful * Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old * Have morning knee stiffness that lasts about 30 minutes * Have a crackling or grinding sound or feeling in the knee Exclusion Criteria: * Have gained or lost more than 11 pounds within 90 days prior to screening * Have had a surgery for obesity or plan to have one in the next 18 months * Have an active knee infection * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure * Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening
Treatments and study arms
Orforglipron
Drug
Administered orally
Placebo
Drug
Administered orally
Primary outcomes
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale ScoreBaseline, Week 72
Study locations
88 locations were listed when this page was built. The first 40 are shown.
Aggarwal and Associates Limited🇨🇦 Brampton, Canada
Study contactContact
Naresh AggarwalPrincipal Investigator
Diex Recherche Inc. Division Joliette🇨🇦 Joliette, Canada
Study contactContact
Jean-Sebastien PaquettePrincipal Investigator
ALPHA Recherche Clinique🇨🇦 Québec, Canada
Study contactContact
Xavier MignaultPrincipal Investigator
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.🇨🇦 Québec, Canada
Study contactContact
Louis BessettePrincipal Investigator
Bluewater Clinical Research Group Inc.🇨🇦 Sarnia, Canada
Study contactContact
John O'MahonyPrincipal Investigator
Winterberry Research Inc.🇨🇦 Stoney Creek, Canada
Study contactContact
Steven ZizzoPrincipal Investigator
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technolo -T🇨🇳 Baotou, China
Study contactContact
Yongfu WangPrincipal Investigator
The Second Affiliated Hospital Chongqing Medical University🇨🇳 Chongqing, China
Study contactContact
Lin TangPrincipal Investigator
The Fourth Affiliated Hospital of Harbin Medical University🇨🇳 Harbin, China
Study contactContact
ZhiFeng ChengPrincipal Investigator
The Second People's Hospital of Hefei🇨🇳 Hefei, China
Study contactContact
Jun YePrincipal Investigator
Jinan Central Hospital🇨🇳 Jinan, China
Study contactContact
Shuya GuoPrincipal Investigator
The First Affiliated Hospital of Henan University of Science &Technology🇨🇳 Luoyang, China
Study contactContact
Xiaofei ShiPrincipal Investigator
Nanjing Medical University - Nanjing Jiangning Hospital🇨🇳 Nanjing, China
Study contactContact
Kun WangPrincipal Investigator
Pingxiang People's Hospital🇨🇳 Pingxiang, China
Study contactContact
Jiankang HuPrincipal Investigator
The First Hospital of Qinhuangdao🇨🇳 Qinhuangdao Shi, China
Study contactContact
Bowei LiuPrincipal Investigator
Huashan Hospital, Fudan University🇨🇳 Shanghai, China
Study contactContact
Weiguo WanPrincipal Investigator
The First Affiliated Hospital of Shantou University Medical College🇨🇳 Shantou, China
Study contactContact
Zhiduo HouPrincipal Investigator
The University of Hong Kong-Shenzhen Hospital🇨🇳 Shenzhen, China
Ling WuPrincipal Investigator
Siteworks GmbH - Bochum🇩🇪 Bochum, Germany
Klinische Forschung Dresden🇩🇪 Dresden, Germany
HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg GmbH / -T🇩🇪 Hamburg, Germany
Klinische Forschung Hamburg🇩🇪 Hamburg, Germany
Klinische Forschung Hannover-Mitte🇩🇪 Hanover, Germany
Siteworks GmbH - Hannover🇩🇪 Hanover, Germany
Klinische Forschung Karlsruhe🇩🇪 Karlsruhe, Germany
Siteworks - Karlsruhe🇩🇪 Karlsruhe, Germany
AmBeNet GmbH🇩🇪 Leipzig, Germany
CDG Studienambulanz Hartard🇩🇪 München, Germany
Dedicated Research Site FutureMeds🇩🇪 Offenbach, Germany
Private Practice - Dr. Jochen Walter🇩🇪 Rendsburg, Germany
Universitaetsklinikum Wuerzburg🇩🇪 Würzburg, Germany
Fukuoka Wajiro Hospital🇯🇵 Fukuoka, Japan
Study contactContact
Daiki OkazakiPrincipal Investigator
Hamanomachi Hospital🇯🇵 Fukuoka, Japan
Study contactContact
Taro MawatariPrincipal Investigator
Shimane University Hospital🇯🇵 Izumo, Japan
Study contactContact
Yuji UchioPrincipal Investigator